Beyond the Standard: Individualized Approaches to Dual Antiplatelet Therapy Gain Attention
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, shared an insightful post on LinkedIn:
”When it comes to dual antiplatelet treatment we are still using a non-individualized approach in our everyday clinical practice for patients after PCI.
However, evidence is accumulating that sex, age, BMI and many more variables may constitute relevant treatment effect modifiers for drugs like clopidogrel, prasugrel or ticagrelor.
See the latest data on DAPT and sex in the European Heart Journal and my Editorial that puts the findings into perspective.”
Read the full article here.
Article: Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment
Author: Dirk Sibbing
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease